US-China trade war sharply escalates

Yesterday evening, US President Trump announced to impose a 10%
tariffs on the so far untaxed imports from China worth about US$
$300bn, beginning on September 1. The decision was obviously
made on the return of Secretary Mnuchin and USTR Lighthizer from
trade talks in Shanghai, where both sides met for the first time in
person since trade talks were resumed.

Highlights:

  • Yesterday evening, US President Trump announced to impose a 10% tariffs on the so far untaxed imports from China worth about US$ $300bn, beginning on September 1, while trade talks should go on.
  • We expect China to retaliate in a measured approach.
  • The new tariffs could lead to an additional loss of GDP growth by about 0.5 pp in China over the medium term. Thus, Beijing will likely step up monetary and fiscal support in a compensatory way.
  • As the new tariffs will hit (so fare spared) US consumption goods imports much more significantly, the measure will likely lead to some upward pressures on inflation in the US. This will also imply a negative impact on US growth, and thus renders Fed cuts more certain.
  • In an initial reaction, US stock markets lost about 1%, China’s markets about 1.4%. However, in our opinion, the 10% increase is not large enough for the knee-jerk reaction to morph into a risk asset meltdown. Given the heightened risks on growth, and the likely bolder easing from central banks, bond yields remain skewed to the downside.
  • The key question is whether Trump will eventually ratchet tariffs up from 10% to 25%. This is not our central scenario, given the associated risk of a US hard landing or even recession ahead of the November 2020 election. However, such a bold move would change our views on risky assets (equities and credit).

Download the full publication below

US-CHINA TRADE WAR SHARPLY ESCALATES

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.